JD Supra Corporate Brief: Drug Pricing in China, Corruption in Brazil, Climate Change in Congress, Antitrust Law in Europe

A Friday in July and you’re reading the JD Supra Corporate Brief? Does it get any better?

China is questioning 60 pharmaceutical companies about their drug pricing (Dechert)

Myriad is going on the litigation offensive to protect its BRCA1 and BRCA2 patents (MBHB)

Even the ITC is targeting patent trolls… (Duane Morris)

Companies operating in Brazil will have a strong incentive to establish and strengthen compliance efforts when a new law goes into effect early next year… (Pepper Hamilton)

It appears that President Obama isn’t waiting around for Congress to address climate change… (Reed Smith)

Prosecuting foreign companies and individuals for theft of US trade secrets isn’t easy… (Orrick)

The SEC just launched three new initiatives targeting fraudulent accounting and securities practices (BakerHostetler)

There’s change afoot in EU antitrust law … and it doesn’t look good for patent licensors (Mintz Levin)

Looking for more? Find it at JD Supra Law News>>